Global Colorectal Cancer Drugs Market 2015-2019 - The Dominance of Biologics

Jul 29, 2015, 10:10 ET from Research and Markets

DUBLIN, July 27, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Global Colorectal Cancer Drugs Market 2015-2019" report to their offering.

The global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.

Biologics are rapidly becoming the treatment of choice for colorectal cancer. Biologics are targeted therapy, which act only on the malignant cells and do not attack the healthy cells. The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab). These biologics together accounted for the major share of the market, and the same trend is expected to continue during the forecast period.

According to the report, colorectal cancers cannot be cured by the currently available therapeutic options. In addition, if it has not metastasized, surgery would be the only option. The chances of cancer recurring near the place of origin are high. The currently available branded and generic drugs are indicated only for off-label treatment use. However, these drugs have many side effects. Hyperbilirubinemia, gastrointestinal perforation, coagulopathy, cardiotoxicity, hemorrhage, hepatotoxicity, neutropenia, proteinuria, thrombocytopenia, ischemia, soft tissue toxicity, pulmonary fibrosis, and increased mortality are some of the significant adverse side effects. Thus, a drug maker has opportunities to exploit and seek a favorable position in the market by addressing these issues.

Further, the report states that many branded drugs available in the market have lost their patents or are expected to lose it during the forecast period.

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer.

Based on the type of molecule, the market is grouped into two categories:

- Biologics - Small molecules

Based on the route of administration, the market is grouped into two categories:

- Oral

- Parenteral

Key Vendors

- Amgen - Bayer - Bristol-Myers Squibb - F. Hoffmann-La Roche - Merck Serono

Other Prominent Vendors

- Accord Healthcare

- Advenchen Laboratories

- Aeterna Zentaris

- AstraZeneca

- Bavarian Nordic

- Biothera

- Boehringer Ingelheim

- Daiichi Sankyo

- Debiopharm

- Eisai

- Eli Lilly

- Immodulon Therapeutics

- Mologen

- Mylan

- Nektar Therapeutics

- Oncothyreon

- Otsuka Pharmaceutical

- Precision Biologics

- Sun Pharmaceutical

- Symphogen

- Taiho

- Takeda

- Teva

- ThromboGenics

- Xbiotech

- Yakult Honsha

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets